SYM Financial Corp’s Stoke Therapeutics STOK Stock Holding History

SYM Financial Corp’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.56M	Buy	+60,071	New	+$1.81M	0.12%	51

Other funds holding STOK

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

Generali Investments Management Ljubljana, Slovenia $517M AUM 27.81% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

SYM Financial Corp's STOK Position: Q3 2026 in Review

SYM Financial Corp opened a new position in Stoke Therapeutics (STOK) in Q3 2026: 60,071 shares worth $1.56M. The stake represents 0.12% of the portfolio and ranks #51 among its holdings.

24 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

SYM Financial Corp held 60,071 shares of Stoke Therapeutics worth $1.56M as of Q3 2026.
Stoke Therapeutics was a new SYM Financial Corp position in Q3 2026.
Stoke Therapeutics made up 0.12% of SYM Financial Corp's portfolio in Q3 2026, its #51 holding.
24 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on SYM Financial Corp's 13F filing for Q3 2026, filed 26 Oct 2026.